Learn with Anil · UPSC Civil Services PYQsMains PYQs →Subscribe ₹149
INS Vikrant and INS Vikramaditya sailing with their carrier battle group

Photo: INS Vikrant and INS Vikramaditya, Indian Navy, GODL-India

UPSC Civil Services (Main) 2024 · GS Paper III

UPSC Mains 2024 GS 3 · Q5: model answer

General Studies Paper III: Technology, Economic Development, Bio-diversity, Environment, Security and Disaster Management · Science and Technology.

Q510 marks150 words2024 · GS Paper III

What is the present world scenario of intellectual property rights with respect to life materials? Although, India is second in the world to file patents, still only a few have been commercialized. Explain the reasons behind this less commercialization.

Syllabus: Science and Technology · IPR and indigenisation of technology

Model answer · free

Patenting life formsTRIPS Article 27.3(b)Section 3(j)Lab-to-market gap

"Life materials" are living organisms and their parts, such as micro-organisms, genes, cells and plant varieties. Since Diamond v Chakrabarty (1980), when the US Supreme Court upheld a patent on an oil-eating bacterium engineered by Ananda Chakrabarty, intellectual property over life has expanded, but within limits set by the WTO's TRIPS Agreement (1995), ethics and biodiversity law. India files more patents than ever, yet few reach the market.

1. Present world scenario of IPR on life materials

  • TRIPS minimum standard (Article 27.3(b)): members may exclude plants, animals and essentially biological processes from patents, but must patent micro-organisms and microbiological processes and protect plant varieties by patents or a sui generis system.
  • Broad protection in the USA: genetically modified organisms, the Harvard "oncomouse" and engineered cells are patentable; but in Myriad Genetics (2013) the Supreme Court held that naturally occurring DNA cannot be patented, while synthetic cDNA can.
  • Ethical limits in Europe: the EU Biotech Directive (1998) bars patents on plant and animal varieties, human cloning, germ-line modification and commercial use of human embryos.
  • Plant breeders' rights: the UPOV Convention protects new varieties; India chose its own PPV&FR Act, 2001, which also protects farmers' rights.
  • Benefit-sharing: the CBD (1992), the Nagoya Protocol (2010) and the WIPO Treaty on Genetic Resources and Associated Traditional Knowledge (2024), which requires patent applicants to disclose the origin of genetic resources, aim to stop biopiracy.
SystemPatentableExcluded
TRIPS (WTO)Micro-organisms, microbiological processesMembers may exclude plants, animals and biological processes
USAGM organisms, engineered cells, synthetic DNANaturally occurring genes (Myriad, 2013)
European UnionBiotech inventions not confined to one varietyPlant and animal varieties; human cloning; germ-line modification
IndiaMicro-organisms, biotech processesPlants, animals, seeds and varieties (Section 3(j)); living things found in nature (Section 3(c))
How major systems treat life materials

2. India's patent surge

  • Rapid growth: 1,10,375 applications were filed in 2024-25, 62% of them by Indian residents, and Indians received 32% of patents granted, against 15% in 2013-14. India is now among the world's leading filers: WIPO ranks its patent office sixth by filings (2025).

3. Reasons for low commercialisation

  • Patents as a metric: institutions are ranked and faculty rewarded for filing patents, not for licensing them, so many are filed with no market in view.
  • Weak technology transfer: few professional technology-transfer offices, little licensing expertise and thin industry–academia links.
  • Low R&D spending: gross R&D spending is only 0.84% of GDP (2023-24), against over 2% in most developed countries.
  • Valley of death: scarce risk capital, pilot plants and manufacturing support to turn prototypes into products.
  • Defensive patents: many patents, including those of foreign firms, protect markets rather than products made in India; Form 27 working statements show many unworked patents.
  • Delays and costs: examination delays, renewal fees and litigation risk lead many patents to lapse.
Research in laboratories and universities
Patent filed and counted for rankings
No licensee, risk capital or pilot plant
Renewal fees unpaid; patent lapses
Where Indian inventions get stuck

4. Way forward

  • Funding for translation: the National IPR Policy (2016) makes commercialisation an objective; the Anusandhan National Research Foundation (2023) and the ₹1 lakh crore RDI scheme (2025) fund industry-linked research.
  • Right incentives: reward licences and royalties rather than filings, and build regional technology-transfer hubs.

The world is moving towards regulated ownership of life, balanced by benefit-sharing. India must convert its patent surge into products through industry links, risk capital and a culture that values licensing over counting.

Every model answer here is free

The ₹149 All-in-One Pass opens the rest of the site for 12 months: UPSC Prelims GS Paper I and CSAT with explanations, practice quizzes and timed tests, UPSC CAPF and EPFO, the previous papers of every APPSC, TSPSC, police and SSC exam, every mock test series and the study books.

₹149 · valid for 12 months from the day you pay, on every exam · pay by UPI, card or net banking

Get it for ₹149